DOCSLIB.ORG

United States Patent Office Patented Aug

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent Office Patented Aug 3,751,562 United States Patent Office Patented Aug. 7, 1973 2 3,751,562 chlorophene, with a gelled oil. The base for these com MEDICATED GELLIED OLS Joseph Nichols, Princeton, N.J., assignor to Princeton positions is preferably a mineral oil gelled by at least one Biomedix incorporated, Princeton, N.Y. polyoxyethylated fatty acid alcohol ether. No Drawing. Continuation-in-part of abandoned applica Accordingly, it is a primary object of the present in tion Ser. No. 28,124, Apr. 13, 1970. This application vention to provide a topical medicament which is free Sept. 22, 1972, Ser. No. 291,239 of the aforementioned and other such disadvantages. Ent. C. A61k 9/06, 27/00 It is another primary object of the present invention U.S. C. 424-45 Clains to provide a carrier for a topical medicament which is clear, Water-soluble, aesthetically pleasing, and non-irri O tating. ABSTRACT OF THE DISCLOSEURE It is another object of the present invention to provide Medicated gelled oils suitable for topical application are a topical antiseptic composition which is relatively in disclosed. The gelled oils which form an ointment base are expensive to manufacture and easy to apply. mineral oils gelled with at least one polyoxyethylated It is still another object of the present invention to pro fatty acid alcohol ether. The base can be compounded 5 vide an antiseptic composition containing iodine, which With any conventional topical medicament for use as a composition is non-irritating, easy to apply, and has a germicide, fungicide, or anesthetic. long-lasting effect. Yet another object of the present invention is to pro This application is a continuation-in-part of co-pending vide an antiseptic composition containing thimerosal, application Ser. No. 28,124, filed Apr. 13, 1970, and now 20 which composition is non-irritating, easy to apply, and abandoned. has a long-lasting effect. This invention relates to topical medicaments and more Certain characteristics of the aforementioned inventive particularly, this invention relates to medicated water. gelled oil composition also make such a composition ex Soluble gelled oils. tremely useful as a carrier for medication used as an anti Over the years there has been an established need for acne aid. Such medications are, for example, sulfur and an effective antiseptic for topical application to the skin, resorcinol. either to disinfect a wound or for a pre-Surgical applica Consistent with the foregoing objects, it is yet another tion. Of the many types of antiseptics devised and used, object of the present invention to provide an anti-acne the most effective and best all around antiseptic has been, composition which is simple and easy to use, non-irritating and still is, iodine. The antibacterial spectrum of iodine 30 to the skin, and does not leave an unsightly residue. is wide and it is potent against viruses and spores of fungi Additionally, for certain specific purposes, other ingre and bacteria as well. Many of the problems resulting from dients such as vitamins A, C, and E may be included in its application in alcohol Solution-stinging, staining of the gelled oil base. skin and clothing, odor, burning of tissue, sensitization According to the present invention, a carrier is pro have in recent years been partly or completely overcome vided for the topical medication, which carrier is a water by water solubilization with complexing agents such as soluble gelled oil comprising a mineral oil and at least polyvinylpyrrolidone and polyoxyethylene surfactants. one polyoxyethylated fatty acid alcohol ether. The poly These new iodine formulations, however, still being liquid, oxyethylated fatty acid alcohol ether can be a saturated continue to present a problem of running on the skin and, or unsaturated compound and preferably, has from about in the case of their use as pre-surgical scrubs, with pooling 40 16 to about 22 carbon atoms in the fatty acid moiety. In and resultant danger of irritation and burns. In this re. particular, the more preferred such polyoxyethylated fatty spect, tincture of iodine was superior to the present iodo acid alcohol ethers are polyoxyethylene (7) oeyl ether phor products in that the alcohol evaporated relatively and polyoxyethylene (10) oley ether. Still more pre rapidly leaving the iodine more or less at the specific site ferred, is a combination of polyoxyethylene (7) oley. desired, 45 ether and polyoxyethylene (15) stearyl ether. Generally, In order to eliminate as many as possible of the above the polyoxyethylated fatty acid alcohol ether is present mentioned disadvantages of known iodine preparations, in an amount from about 18 to about 25% by weight of many hospitals have adopted other types of compounds the total composition, which composition includes the for pre-surgical antiseptic use such as merbromin and mineral oil, a suitable topical medicament in an effective thimerosal. The most common composition used for this 50 amount, and a suitable diluent. Preferably, the polyoxy purpose is a hexachlorophene liquid soap such as that ethylated fatty acid alcohol ether is present in an amount Sold under the trade mark "pHisoHex' which is a solu from about 19 to about 21% by weight of the total com tion of hexachlorophene and a potassium soap. Normally, position. The mineral oil is present in an amount of from the area to be treated with the hexachlorophene soap about 18 to about 30% by weight of the total composi must be scrubbed with the same prior to any surgical 55 tion and, preferably, in the range of from about 20 to procedure. This material is also used as a scrub for the 25% by weight of the total composition. hands and other areas wherein the long-term effectiveness The gel system has been found to have excellent surface is needed. active, spreading, and penetrating characteristics. It has Disadvantages associated with such commonly used ma both hydrophilic and lipophilic properties which enhance terials as liquid hexachlorophene preparations are the gen 60 percutaneous absorption. It improves contact of the anti eral messiness of their application and certain harmful septic with the tissue. The carrier therefore contributes physiological effects hexachlorophene has been found to to effectivensss of the antiseptic contained therein. possess. It is also well known that while hexachlorophene Suitable medicaments for topical use as disinfectants or does not have certain of the disadvantages of iodine, it germicides, fungicides, and local anesthetics are as fol is, by the same token, not as effective as iodine as a germi 65 lows: cide. nitrofurazone It has now been found that the disadvantages associated furazolidone with the antiseptic preparations of the prior art can be nifuroxime eliminated by compounding suitable antiseptic agents, for bacitracin example, iodine haloacetamide, chlorhexidine, merbromin O chloamphenicol (Mercurochrome), thimerosal (Merthiolate) and hexa chlortetracycline 3,751,562 3. 4. dimethylchlortetracycline This invention is further illustrated by the following gramicidin examples which are merely illustrative and are not meant nystatin to be in any way limiting. oleandomycin oxytetracycline EXAMPLE 1. polymyxin Polyoxyethylene (7) oleyl ether was prepared by the tetracycline following procedure: tyrothricin Oleyi alcohol (381 grams) was dehydrated by heating merbromin to 150 C. under vacuum for thirty minutes while bub furaltadone 10 bling in a stream of dry nitrogen. The temperature was nitrofurantoin raised to 185, two pellets of sodium hydroxide were chlordantoin added and ethylene oxide gas, which had been scrubbed benzalkonium chloride with soda lime and dry sodium hydroxide, was passed butethamine hydrochloride into the mixture. The temperature of the reaction mixture butyl aminobenzoate 5 was maintained at 185-190° C. After 27 hours, 440 grams dibucaine hydrochloride ethylene oxide has been taken up. The reaction mixture ethylaminobenzoate was cooled to 150 and was degassed under vacuum with lidocain a stream of nitrogen for 40 minutes. The product obtained pramoxine hydrochloride was a light amber colored oil which partially solidified tetracaine 20 on cooling. amolanone hydrochloride EXAMPLE 2 diperodon hydrochloride orthocaine Polyoxyethylene (15) steary ether was prepared by a benzethonium chloride similar procedure: hexylresorcinol Stearyl alcohol (270.5 grams) was dried by heating to 25 150 C. under vacuum while bubbling in a stream of dry hexachlorophene nitrogen for 30 minutes. A pellet of sodium hydroxide iodine was added and the material was heated to 185 C. The sulfur reaction mixture was kept at 185-190° C. while a vig resorcinol orous stream of ethylene oxide gas, scrubbed with soda chlorhexidene 30 lime and sodium hydroxide was added. After 23 hours, iodoacetamide 660 grams of ethylene oxide has been taken up by the bromoacetamide mixture. The product was degassed by bubbling a stream chloroacetamide of dry nitrogen gas through the material at 150 C. under thimerosal vacuum for 30 minutes. The product was a light yellow The most preferred of these disinfectant materials are 35 oil which solidified on cooling. iodine, chlorhexidine, iodoacetamide, thimerosal, and, for certain applications, hexachlorophene is also preferred. EXAMPLE 3 In many instances, a combination of iodine and hexa A topical antiseptic was prepared according to this in chlorophene is desirable. Generally, the iodine should be vention having the following composition: present in an amount of from about 0.5 to about 2% by 40 weight of the total composition, and preferably, about Ingredients: Percent 1% by weight of the total composition. When hexachlo Mineral oil ---------------------- as a 23.59 rophene is used, it should be present in an amount from Polyoxyethylene (15) stearyl ether --------- 11.00 about 0.5 to about 3% by weight of the total composi Polyoxyethylene (7) oley ether ----------. 9.43 tion, and preferably 1% by weight of the total compo 45 Iodine --------------------------------- 0.94 sition. Deionized Water ------------------------- 55.03 Most of the acne preparations on the market contain The composition was prepared as follows: sulfur in dispersed form in concentrations of 1 to 5%.
Load more

Recommended publications
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,039,940 Perrault Et Al
    US0060399.40A United States Patent (19) 11 Patent Number: 6,039,940 Perrault et al. (45) Date of Patent: Mar. 21, 2000 54) INHERENTLY ANTIMICROBIAL 5,563,056 10/1996 Swan et al.. QUATERNARY AMINE HYDROGEL WOUND 5,599.321 2/1997 Conway et al.. DRESSINGS 5,624,704 4/1997 Darouiche et al.. 5,670.557 9/1997 Dietz et al.. 75 Inventors: James J. Perrault, Vista, Calif.; 5,674.561 10/1997 Dietz et al.. Cameron G. Rouns, Pocatello, Id. 5,800,685 9/1998 Perrault. FOREIGN PATENT DOCUMENTS 73 Assignee: Ballard Medical Products, Draper, Utah 92/06694 4/1992 WIPO. WO 97/14448 4/1997 WIPO. 21 Appl. No.: 09/144,727 OTHER PUBLICATIONS 22 Filed: Sep. 1, 1998 I. I. Raad, “Vascular Catheters Impregnated with Antimi crobial Agents: Present Knowledge and Future Direction,” Related U.S. Application Data Infection Control and Hospital Epidemiology, 18(4): 63 Continuation-in-part of application No. 08/738,651, Oct. 28, 227–229 (1997). 1996, Pat. No. 5,800,685. R. O. Darouiche, H. Safar, and I. I. Raad, “In Vitro Efficacy of Antimicrobial-Coated Bladder Catheters in Inhibiting 51) Int. Cl." .......................... A61K31/785; A61F 13/00 Bacterial Migration along Catheter Surface,” J. Infect. Dis., 52 U.S. Cl. ..................................... 424/78.06; 424/78.08; 176: 1109-12 (1997). 424/78.35; 424/78.37; 424/443; 424/445 W. Kohen and B. Jansen, “Polymer Materials for the Pre 58 Field of Search ..................................... 424/443, 445, vention of Catheter-related Infections.” Zbl Bakt., 283: 424/78.06, 78.07, 78.08, 78.35, 78.37 175-186 (1995).
    [Show full text]
  • Identification of Drug Candidates That Enhance Pyrazinamide Activity from a Clinical Drug Library
    bioRxiv preprint doi: https://doi.org/10.1101/113704; this version posted March 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library Hongxia Niub, a, Chao Mac, Peng Cuid, Wanliang Shia, Shuo Zhanga, Jie Fenga, David Sullivana, Bingdong Zhu b, Wenhong Zhangd, Ying Zhanga,d* a Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA b Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China c College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China d Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China *Correspondence: Ying Zhang, E-Mail: [email protected] Tuberculosis (TB) remains a leading cause of morbidity and mortality globally despite the availability of the TB therapy. 1 The current TB therapy is lengthy and suboptimal, requiring a treatment time of at least 6 months for drug susceptible TB and 9-12 months (shorter Bangladesh regimen) or 18-24 months (regular regimen) for multi-drug-resistant tuberculosis (MDR-TB). 1 The lengthy therapy makes patient compliance difficult, which frequently leads to emergence of drug-resistant strains. The requirement for the prolonged treatment is thought to be due to dormant persister bacteria which are not effectively killed by the current TB drugs, except rifampin and pyrazinamide (PZA) which have higher activity against persisters.
    [Show full text]
  • Risks to Health and the Environment Related to the Use of Mercury Products
    Ref. Ares(2015)4242228 - 12/10/2015 Risks to Health and the Environment Related to the Use of Mercury Products Final Report prepared for The European Commission, DG Enterprise by Risk & Policy Analysts Limited, Farthing Green House, 1 Beccles Road, Loddon, Norfolk, NR14 6LT Tel: 01508 528465 Fax: 01508 520758 Email: [email protected] Web: www.rpaltd.co.uk RPA REPORT - ASSURED QUALITY Project: Ref/Title J372/Mercury Approach: In accordance with the Contract, Scoping Meeting with the Commission and associated discussions Report Status: Final Report Authors: Dr P Floyd & P Zarogiannis, RPA Dr M Crane, Crane Consultants Prof S Tarkowski, Nofer Institute of Occupational Medicine (Poland) Prof V Bencko, Charles University of Prague Approved for Issue by: Ms M Postle, Director Date: 9 August, 2002 If printed by RPA, this report will be on chlorine free, 100% recycled paper. Risk & Policy Analysts EXECUTIVE SUMMARY Overview Mercury and its compounds are hazardous materials which may pose risks to people and to the environment. This report presents an assessment of the risks associated with the use of mercury in a range of products. The key requirements of the study were: • to identify usage of mercury in dental amalgam, batteries, measuring instruments (such as thermometers and manometers), lighting, other electrical components and other lesser uses; • to review data used to evaluate the toxicity of mercury and mercury compounds to humans and to the environment; • to derive predicted environmental concentrations (PECs) associated with use of the products under consideration and compare with those associated with other sources of mercury; and • to characterise the associated risks.
    [Show full text]
  • Survey of Mercury and Mercury Compounds
    Survey of mercury and mercury compounds Part of the LOUS-review Environmental Project No. 1544, 2014 Title: Authors and contributors: Survey of mercury and mercury compounds Jakob Maag Jesper Kjølholt Sonja Hagen Mikkelsen Christian Nyander Jeppesen Anna Juliana Clausen and Mie Ostenfeldt COWI A/S, Denmark Published by: The Danish Environmental Protection Agency Strandgade 29 1401 Copenhagen K Denmark www.mst.dk/english Year: ISBN no. 2014 978-87-93026-98-8 Disclaimer: When the occasion arises, the Danish Environmental Protection Agency will publish reports and papers concerning research and development projects within the environmental sector, financed by study grants provided by the Danish Environmental Protection Agency. It should be noted that such publications do not necessarily reflect the position or opinion of the Danish Environmental Protection Agency. However, publication does indicate that, in the opinion of the Danish Environmental Protection Agency, the content represents an important contribution to the debate surrounding Danish environmental policy. While the information provided in this report is believed to be accurate, the Danish Environmental Protection Agency disclaims any responsibility for possible inaccuracies or omissions and consequences that may flow from them. Neither the Danish Environmental Protection Agency nor COWI or any individual involved in the preparation of this publication shall be liable for any injury, loss, damage or prejudice of any kind that may be caused by persons who have acted based on their understanding of the information contained in this publication. Sources must be acknowledged. 2 Survey of mercury and mercury compounds Contents Preface ...................................................................................................................... 5 Summary and conclusions ......................................................................................... 7 Sammenfatning og konklusion ................................................................................ 14 1.
    [Show full text]
  • Scheduling: Delegates Reasons for Interim Decisions
    INTERIM DECISIONS & REASONS FOR DECISIONS BY THE DELEGATE OF THE SECRETARY TO THE DEPARTMENT OF HEALTH AND AGEING INVITATION FOR COMMENT Notice under subsection 42ZCZP of the Therapeutic Goods Regulations 1990 (the Regulations) The Delegate of the Secretary to the Department of Health and Ageing hereby gives notice of the delegate’s interim decisions under subsection 42ZCZP of the Therapeutic Goods Regulations 1990. This notice provides the interim decisions of the delegate, the reasons for those decisions and invites comment from the applicant and parties who made a valid submission in response to the original invitation for comment (published on 29 September 2010 at http://www.tga.gov.au/newsroom/consult-scheduling-acmcs.htm). Edited versions of these submissions are available at http://www.tga.gov.au/industry/scheduling- decisions.htm. If no submissions were received to the original invitation, then the delegate may choose to confirm the interim decision as the final decision. Submissions must be relevant to the proposed amendment, must address a matter mentioned in section 52E of the Therapeutic Goods Act 1989 and be received by the closing date (2 March 2011). Submissions from parties other than those who made a valid submission in response to the original invitation or the applicant, or those received after the closing date, need not be considered by the delegate. Please note that all valid submissions received on or before the closing date will be published following removal of confidential information. It is up to the person making the submission to highlight any information which they wish to be considered as confidential.
    [Show full text]
  • FOI 161-112 Document 1
    \/ Fw: IDC - Mercury L fy [SEC=:UNCLASSIFIED] 09/12/2010 04:23 PM - This is the fi rst of two emails I will send - this is our response to the questions posed by the UNEP f""I secretariat after the first in June. INC ...., C Kind regards, QJ E :::l ..*******��***************�************ u o International Coordination Team c Office of Parliamentary and Strategic Support Therapeutic Goods Administration E-mail: [email protected] ----- Forwarded n 09/12/20"10 04:21 PM ---_. To 'ilenvironmentgov,au> · cc !ilenvironment.gov,au>, environment.gov,au>_ "" 11/11/2010 .. .. 02:14 PM Subject Re: IDC - Mercury LBI- Friday 23 July [SEC=UNCLASSIFIED} Dear_ Please find attached TGA's contribution to the mercury data gaps identified by the UNEP Secretariat. Should you have any queries or concerns relating to tllis information, we would be very happy to discuss these at our meeting tomorrow (Friday 12 November at 3pm), TGA participants at tomorrow's meeting will be: Devices Authorisation Office of Scientific Evaluation Services _ill also be there, representing the International Coordination team. Please note that we are correctly identified as stakeholders for the Regulation sector (arrangements for labelling products containing mercury), but mistakenly included as a stakeholder for the sector for uni ntentional emission (biomedical waste i Ilcineration), Kind regards, International Coordination Tearn Office of Parliamentary aild Strategic Support Therapeutic Goods Administration E�mail: [email protected] o - Mercury in ther�peutic products - Response for UNEP INC Oct 201 O.DOCX Dear Colleagues FOl owlng u� ercury �BI meeting on FridLY'23 July, we would li ke to t from t� �C � M request for )tell assl�� ce In addressing the mercury data gaps that the UNEP Secretariat has identified.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Mercury Survey College of Pharmacy
    Appendix A - Survey Tools ACADEMIC LABORATORY MERCURY MINIMALIZATION | SECURED DOCUMENT Academic Affairs Laboratory Safety Mercury Survey College of Pharmacy Number: AALSSD 2-30-3500 CP-F01 Author: Anne Hawkins Effective Date: Revision Date: Accepted/ Issued: Name of individual filling out survey: Title: Phone: Please indicate if the following mercury sources are located or used in your Department I. Equipment: Barometers Batteries Centrifuges Fever Thermometers Hood Manometer Sphygmomanometers Thermostats Other II. Chemicals/Staining Solutions & Preservatives: Mercury iodide Mercury (I) Bromide Mercury (I) Carbonate Mercury (I) Chloride Mercury (I) Chromate Mercury (I) Dichromate Mercury (I) Nitrate Mercury (I) Nitrate Mercury (I) Oxide Mercury (I) Sulfate Mercury (I) Sulfide Mercury (II) Acetate Mercury (II) Ammonium Thoocyanate Mercury (II) Bromate Mercury (II) Bromide Mercury (II) Carbonate Mercury (II) Chlorate Mercury (II) Chloride Mercury (II) Chromate Mercury (II) Dichromate Mercury (II) Hydrogen Carbonate Mercury (II) Hydroxide Mercury (II) Iodate Mercury (II) Nitrate Mercury (II) Nitrate Monohydrate Mercury (II) Nitrite Mercury (II) Oxide Mercury (II) Nitride Mercury (II) Phosphate Mercury (II) Sulfate Mercury (II) Sulfide Mercury (II) Thiosulfate Commercial Chemical Products Acetate Acetic acid Alum Ammonium reagent/Stone analysis kit Antibody test kits Antigens Buffers Chloride Diluents Ethanol Fixatives Immunoelectrophoresis reagents Immunofixationphoresis reagents: Immu-sal Potassium hydroxide Shigella bacteria Sodium hypochlorite Sulfuric acid Thimerosal T Tracer kits Urine analysis reagents Other III. Drug & Biologic Products- Thimerosal: Akorn Inc. AK Spore Ophthalmic Solution AK Spore HC Ophthalmic Combo Drops Fluoracaine Ophthalmic Solution AK Spore HC Otic Suspension Alcon Laboratories Profenal 1% Ophthalmic Solution Adsorbonac 2% Ophthalmic Solution Adsorbonac 5% Ophthalmic Solution Allergan America Ocufen Ophthalmic Solution Poly Pred Ophthalmic Suspension Allergan Inc.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated July 30, 2020 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Notice of Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List • Additions to category 1: Betahistine Hydrochloride L-Proline Citrulline Papaverine Hydrochloride* Copper Gluconate Phosphatidylcholine Diiodohydroxyquinoline Podophyllum Resin Glucosamine Sulfate Potassium Chloride Sodium Molybdate Glucosamine Sulfate Sodium Chloride Sodium Nitroprusside Hydrochloric Acid* Sodium Selenite/Sodium Selenite Pentahydrate* Ibutamoren Mesylate Trichloroacetic Acid* L-Citrulline* Ubidecarenone (Coenzyme Q10)* L-Lysine * Bulk drug substance is currently in Category 3 and is being moved to Category 1. • Minor revision to entry in Category 1 to correct a misspelling: o Correct the misspelling of “cimatidine” to “cimetidine” 1 Updated July 30, 2020 503B Category 1: Bulk Drug Substances Under Evaluation • 5-Methyltetrahydrofolate Calcium • Chromic Chloride • 17-alpha-Hydroxyprogesterone • Chromium chloride/ Chromium Chloride • Acetylcysteine Hexahydrate • Acyclovir • Ciclopirox Oleate • Adapalene • Cimetidine • Adenosine • Ciprofloxacin HCl • Allantoin • Citric Acid Anhydrous • Alpha Lipoic Acid • Citrulline/L-Citrulline • Alprostadil • Clindamycin Phosphate
    [Show full text]
  • Greener Hospitals U R T EN Z S T F a H C S N E S Improving IS W Environmental Performance
    please feel free to visit our website atwww.bms.com. tovisitourwebsite please feelfree our policiesandprocedures, Squibb, wouldlikeadditionalinformationonBristol-Myers you If www.wzu.uni-augsburg.de. at ScienceCenterplease visitourwebsite additionalinformationontheEnvironmental For ispossible. Thus, innovation practicalapplications. involving useful forprojects industrysectors,whichisparticularly various withdecision-makersfrom us todealdirectly WEC enables The partnershipwiththe Umwelt. Wissenschaftszentrum located adjacenttothe Centeris Environment World ofthe office thattheEuropean for ourwork a majoradvantage itis Therefore, understanding oftechnicalandindustrialissues. athorough science requires inenvironment Progress the sustainablehandlingofsubstances,materialsandenergy. foraspecifiedperiodontopicswithinthecontextofourcentraltheme - towork Umwelt Wissenschaftszentrum setupat are groups usuallytakenforgranted.Research which are methods, to aquestioningofthetraditionalacademicdivisionsandfield-specificworking otherfieldsofstudyshouldlead withscientistsfrom The exchange staff. university our own othercountrieswillcomplementthepotentialof andfrom otheruniversities scientists from The participationof fields. different from thecollaborationofresearchers studied through topicscanonlybefittingly dialogue.Environmental ofinterdisciplinary energy productive focusingonthe are this,we achieve To Studies. inthefieldofEnvironmental developments andtechnological research innovative aimistostimulatecross-disciplinary, Our research. environmental
    [Show full text]